
RNA-binding protein interactions: methodology for detection and examples in disease

Evgenia Ntini evgenia.ntini@imbb.forth.gr RNA & Gene Regulation IMBB-FoRTH




RNA-binding proteins in gene expression:

- Fundamental co-transcriptional and post-transcriptional roles
- RNA processing (capping, splicing, polyadenylation)
- Stability (Turnover rates)
- Localization/Nuclear export




RNA-binding protein interactions: Deregulation in several diseases Classic RBPs: characterized RNA-binding domains (RBDs) (defined 3D structures)



PMID: 33235359


https://emea.illumina.com/science/sequencing-method-explorer.html




Unveiling the hidden function of long non-coding RNA by identifying its major partner-protein Yang et al., Cell & Bioscience 5:59 (2015)

Doi:10.1186/s13578_015_0050_x

https://emea.illumina.com/science/sequencing-method-explorer.html






From: Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Van Nostrand et al., Nature Methods 2016

• Van Nostrand et al., Nature 2020. A large-scale binding and functional map of human RNA-binding proteins PMID: 32728246


• Van Nostrand EL, et al. Genome Biol. 2020. Principles of RNA processing from analysis of enhanced CLIP maps for 150 RNA binding proteins.

PMID: 32252787




From: A large-scale binding and functional map of human RNA-binding proteins


Disease-associated RBPs




Mutations in RBP genes and potential effects



Protein-protein networks of disease-associated mutations





Example 1. fragile X-associated tremor ataxia syndrome (FXTAS) / Fragile X syndrome (FXS)




Example 2. Somatic mutations in RNA processing factors (involved in splicing): Like RBM10 in numerous cancers, or PRP8 (core spliceosome component)


Example 3. Mutated RBPs in ALS







Example 4. RBP-IncRNA interaction networks and their importance in disease The CCT3-*LINC000326* interaction regulates lipid metabolism in HCC Nørskov Søndergaard et al., Gut 2022;0:1–12. doi:10.1136/gutjnl-2021-325109





Are RBPs druggable?

RNA-based or RNA-targeted therapeutics

Targeting RNA-protein interactions (or RNA elements designated for/stabilized by protein binding), like with the FDA-approved *branaplam* small molecules: Recognition of a target-specific RNA element in conjunction with a (general) RBP component (of cellular metabolism or regulatory networks)may help achieve both **specificity** (via the sequence-specific RNA targeted component) and **affinity** (due the high information content of a protein surface).

Reprogramming RNA processing: an emerging therapeutic landscape Neil et al., 2021; doi.org/10.1016/j.tips.2022.02.011






Spiranza (antisense) – FDA approved

Small molecules -splicing modifiers (~ branaplam FDA approved)

- Palacino et al., SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice. Nature Chemical Biology 11, p 511–517 (2015)
- Sivaramakrishnan et al., Nature Communications 2017 8(1):1476. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. PMID: 29133793



More references:

Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. Nat. Rev. Genet. 15, 829–845 (2014).

Hentze, M. W., Castello, A., Schwarzl, T. & Preiss, T. A brave new world of RNA-binding proteins. Nat. Rev. Mol. Cell Biol. 19, 327–341 (2018).

Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. Nat. Rev. Genet. 15, 829–845 (2014).

Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1393–1406 (2012).

Baltz, A. G. et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol. Cell 46, 674–690 (2012).

Castello, A. et al. Comprehensive identification of RNA-binding domains in human cells. Mol. Cell 63, 696–710 (2016). RBDmap: a method for the high-throughput identification of RBDs within RBPs. Peptides adjacent to the actual RNA-binding residues are identified.

Noncoding RNA therapeutics — challenges and potential solutions Winkle et al. Nature Reviews Drug Discovery volume 20, pages 629–651 (2021)

Advances in oligonucleotide drug delivery Thomas C. Roberts, Robert Langer & Matthew J. A. Wood Nature Reviews Drug Discovery volume 19, pages 673–694 (2020) (incl. Table with FDA approved ASO, and ASObased platfoms